| Active substance | Ibrutinib |
| Holder | Janssen-Cilag |
| Status | Closed |
| Indication | Patients suffering from relapsed or refractory lymphocytic leukaemia/small lymphocytic lymphoma |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 14/01/2016 |
Imbruvica®
Last updated on 13/09/2024